I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 8 January 2013

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

1 Name of Instrument

 (1) This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2013 (No. 1).

 (2) This Instrument may also be cited as PB 1 of 2013.

2 Commencement

This Instrument commences on 1 February 2013.

3 Amendment of National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

 Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).

Schedule 1 Amendments

[1]                Schedule 1, column headed “Determined Quantity”

omit values in all instances where displayed in the column headed “Determined Quantity” for all Listed Drugs, except for:

Methoxyflurane

which retains the value “1” in the column headed “Determined Quantity”

[2]                Schedule 1, entry for Alendronic Acid in the form Tablet 70 mg (as alendronate sodium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[3]                Schedule 1, entry for Atenolol in the form Tablet 50 mg

omit from the column headed “Brand”: Atenolol generichealth  substitute: Atenolol GH

[4]                Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate)

omit from the column headed “Responsible Person” for the brand “Iscover”: BQ substitute: AV

[5]                Schedule 1, entry for Clopidogrel with aspirin in the form Tablet 75 mg (as hydrogen sulfate)-100 mg

omit from the column headed “Responsible Person” for the brand “DuoCover”:  BQ substitute: AV

[6]                Schedule 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 50 mg [Max Quantity 20; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[7]                Schedule 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 50 mg [Max Quantity 100; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[8]                Schedule 1, entry for Exemestane

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[9]                Schedule 1, entry for Fludarabine in the form Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[10]            Schedule 1, entry for Gabapentin in each of the forms: Capsule 100 mg; Capsule 300 mg; Capsule 400 mg; and Tablet 800 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[11]            Schedule 1, entry for Gemcitabine in each of the forms: Powder for I.V. infusion 200 mg (as hydrochloride); Powder for I.V. infusion 1 g (as hydrochloride); and Powder for I.V. infusion 2 g (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[12]            Schedule 1, entry for Irbesartan in each of the forms: Tablet 75 mg; Tablet 150 mg; and Tablet 300 mg

omit from the column headed “Responsible Person” for the brand “Avapro”: BQ substitute: AV

[13]            Schedule 1, entry for Irbesartan with Hydrochlorothiazide in the form Tablet 150 mg-12.5 mg

omit from the column headed “Responsible Person” for the brand “Avapro HCT 150/12.5”: BQ substitute: AV

[14]            Schedule 1, entry for Irbesartan with Hydrochlorothiazide in the form Tablet 300 mg-12.5 mg

omit from the column headed “Responsible Person” for the brand “Avapro HCT 300/12.5”: BQ substitute: AV

[15]            Schedule 1, entry for Irbesartan with Hydrochlorothiazide in the form Tablet 300 mg-25 mg

omit from the column headed “Responsible Person” for the brand “Avapro HCT 300/25”: BQ substitute: AV

[16]            Schedule 1, entry for Lercanidipine in each of the forms: Tablet containing lercanidipine hydrochloride 10 mg; and Tablet containing lercanidipine hydrochloride 20 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[17]            Schedule 1, entry for Letrozole

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[18]            Schedule 1, entry for Lisinopril in the form Tablet 5 mg

omit:

[19]            Schedule 1, entry for Metronidazole

omit:

substitute:

[20]            Schedule 1, entry for Nebivolol

omit from the column headed “Responsible Person” (all instances): CS substitute: FK

[21]            Schedule 1, entry for Oxaliplatin in each of the forms: Solution concentrate for I.V. infusion 50 mg in 10 mL; Solution concentrate for I.V. infusion 100 mg in 20 mL; and Solution concentrate for I.V. infusion 200 mg in 40 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[22]            Schedule 1, entry for Oxybutynin in the form Transdermal patches 36 mg, 8

omit from the column headed “Responsible Person”:  HH  substitute: GM

[23]            Schedule 1, entry for Paclitaxel in each of the forms: Solution concentrate for I.V. infusion 30 mg in 5 mL; Solution concentrate for I.V. infusion 100 mg in 16.7 mL; and Solution concentrate for I.V. infusion 300 mg in 50 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[24]            Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg [Max Quantity 30; Number of Repeats 5]

omit:

[25]            Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 10 mg [Max Quantity 30; Number of Repeats 11]

omit:

[26]            Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg [Max Quantity 30; Number of Repeats 5]

omit:

[27]            Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 20 mg [Max Quantity 30; Number of Repeats 11]

omit:

[28]            Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg [Max Quantity 30; Number of Repeats 5]

omit:

[29]            Schedule 1, entry for Pravastatin in the form Tablet containing pravastatin sodium 40 mg [Max Quantity 30; Number of Repeats 11]

omit:

[30]            Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 5]

omit:

[31]            Schedule 1, entry for Simvastatin in the form Tablet 10 mg [Max Quantity 30; Number of Repeats 11]

omit:

[32]            Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 5]

omit:

[33]            Schedule 1, entry for Simvastatin in the form Tablet 20 mg [Max Quantity 30; Number of Repeats 11]

omit:

[34]            Schedule 1, entry for Simvastatin in the form Tablet 40 mg [Max Quantity 30; Number of Repeats 5]

omit:

[35]            Schedule 1, entry for Simvastatin in the form Tablet 40 mg [Max Quantity 30; Number of Repeats 11]

omit:

[36]            Schedule 1, entry for Simvastatin in the form Tablet 80 mg [Max Quantity 30; Number of Repeats 5]

omit:

[37]            Schedule 1, entry for Simvastatin in the form Tablet 80 mg [Max Quantity 30; Number of Repeats 11]

omit:

[38]            Schedule 1, entry for Sumatriptan in the form Tablet 50 mg (as succinate) for the following brands only:

APO-Sumatriptan; Chem mart Sumatriptan; Imigran; Sumagran 50; Sumagran Aspen 50; Sumatab;
and Terry White Chemists Sumatriptan

omit from the column headed “Pack Quantity”: 4 substitute: 2

[39]            Schedule 1, entry for Testosterone in each of the forms: Transdermal patches 12.2 mg, 60; and Transdermal patches 24.3 mg, 30

omit from the column headed “Responsible Person”:  HH  substitute: GM

[40]            Schedule 1, entry for Topotecan

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[41]            Schedule 1, entry for Tramadol in each of the forms: Tablet (sustained release) containing tramadol hydrochloride 100 mg; Tablet (sustained release) containing tramadol hydrochloride 150 mg; and Tablet (sustained release) containing tramadol hydrochloride 200 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[42]            Schedule 1, entry for Tramadol in the form Injection containing tramadol hydrochloride 100 mg in 2 mL

omit from the column headed “Brand”: Tramahexal substitute: Tramadol Sandoz

[43]            Schedule 1, entry for Vinorelbine in each of the forms: Solution for I.V. infusion 10 mg (as tartrate) in 1 mL; and Solution for I.V. infusion 50 mg (as tartrate) in 5 mL

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[44]            Schedule 3, details relevant to Responsible person code FK

omit: Invida Australia Pty Ltd substitute: A.Menarini Australia Pty Ltd

[45]            Schedule 3, after details relevant to Responsible person code XM

insert:

[46]            Schedule 4, Part 1, entry for Metronidazole

substitute:

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.comlaw.gov.au